IGI Logo

Aurobindo Pharma is currently trading at Rs. 1478.15, up by 14.55 points or 0.99% from its previous closing of Rs. 1463.60 on the BSE.

The scrip opened at Rs. 1488.50 and has touched a high and low of Rs. 1496.15 and Rs. 1474.65 respectively. So far 41803 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1550.00 on 21-May-2026 and a 52 week low of Rs. 1017.00 on 02-Sep-2025.

Last one week high and low of the scrip stood at Rs. 1,550.00 and Rs. 1,365.25 respectively. The current market cap of the company is Rs. 85296.90 crore.

The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 41.11% and 7.08% respectively.

Aurobindo Pharma has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Tofacitinib Tablets, 5 mg and 10 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xeljanz Tablets, 5 mg and 10 mg, of PF Prism C.V.

The product will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of the company and will be launched immediately. According to IQVIA MAT data for the twelve months ending April 2026, Tofacitinib Tablets, 5 mg and 10 mg have an estimated market size of around $494 million in the US. The company now has a total of 586 ANDA approvals (561 final approvals and 25 tentative approvals) from USFDA.

Tofacitinib Tablets are indicated for: i) the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate, ii) the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs), iii) the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or who are intolerant to TNF blockers.